Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever

Leukemia and Lymphoma

Volumn 20, Issue 3-4, 1996, Pages 333-336

  Kitay Cohen, Y ^b   Lishner, M ^a   Shelef, A ^b   Ravid, M ^b   Manor, Y ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Bone marrow involvement; Chemotherapy; Granulocytopenia; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BACTEREMIA; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; FEVER; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; RISK FACTORS;

EID: 0029564215     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609051627     Document Type: Article

References (13)

1. Rodriguez, V., Cabanilas, F., Burgess, M. A., McKelvey, E. M., Valdvieso, M., Bodey, G. P. et al. (1977) Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood. 49, 325-333.
2. McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R. et al. (1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1484-1493.
3. Canellos, G. P., Skarin, A. T., Klatt, M. M., Rosental, D. S., Case, D. C., Pinlus, G. S. et al. (1987) The M-BACOP combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Sem. in Hematol., 24, 2-7, (Suppl 1).
4. Laurence, T., Coleman, M., Allen, S. L., Silver, R. T. and Pasmantier, M. (1982) Combination Chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann. Int. Med., 97, 190-195.
5. Kilmo, P. and Connors, J. M. (1987) Updated clinical experience with MACOP-B. Sem. in Hematol., 24, 26-34.
6. Simon, R., Durrleman, S., Hoppe, R. T., Bonadonna, G., Bloomfield, C. D. and Rudders, R. A. (1988) The non-Hodgkin's lymphoma pathologic classification project. Long term follow up of 1153 patients with non-Hodgkin's lymphoma. Ann. Int. Med., 109, 939-945.
7. Portlock, C. S. (1990) Non-Hodgkin's lymphoma. Advances in diagnosis, staging and management. Cancer, 65, 718-722.
8. Coleman, M. (1985) Chemotherapy forlarge cell lymphoma: optimism and caution. Ann. Int. Med., 103, 140-142.
9. Bishop, J.F., Schimpff, S. C., Diggs, C.H. and Wiernik, P.H. (1981) Infections during intensive chemotherapy for non-Hodgkin's lymphoma. Ann. Int. Med., 95, 549-559.
10. Fisher, R. I., DeVita, V. T., Johnson, B. L., Simon, R. and Young, R. C. (1977) Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J. Med., 63, 177-182.
11. Armitage, J. O., Dick, F. R., Corder, M. P., Gameau, S. C., Pltaz, C. E. and Slymen, D. J. (1982) Predicting therapeutic outcome in patients with diffuse histicytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer, 50, 1695-1702.
12. Cowan, R. A., Jones, M., Harris, M., Steward, W. P., Radford, J. A., Wagstaft, J. et al. (1989) Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Brit. J. Cancer, 59, 276-282.
13. Danieu, L., Wong, B. and Clarkson, B. (1986) Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res., 46, 5327-5329.